Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Chakrabarty2010 - A control theory approach to cancer remission aided by an optimal therapy

ABSTRACT: This is a reinvestigation of a previous model depicting cancer remission. It involves application of mathematical tools from control theory to assess the optimal approach during the use of Adaptive Cellular Immunotherapy and interleukin-2 treatment.

SUBMITTER: Johannes Meyer

PROVIDER: BIOMD0000000777 | BioModels | 2021-10-01

REPOSITORIES: BioModels

ACCESS DATA

Json Xml

Publications

Delay-induced model for tumor-immune interaction and control of malignant tumor growth.

Banerjee Sandip S Sarkar Ram Rup RR

Bio Systems 20071024 1

The paper deals with the qualitative analysis of the solutions of a system of delay differential equations describing the interaction between tumor and immune cells. The asymptotic stability of the possible steady states is showed and the occurrence of limit cycle of the system around the interior equilibrium is proved by the application of Hopf bifurcation theorem by using the delay as a bifurcation parameter. The length of the delay parameter for preserving stability of the system is also esti ...[more]

PMID: 18083299

Similar Datasets

Khajanchi2015 - The combined effects of optimal control in cancer remission

Project description:The combined effects of optimal control in cancer remission SubhasKhajanchi DibakarGhosh Abstract We investigate a mathematical model depicting the nonlinear dynamics of immunogenic tumors as envisioned by Kuznetsov et al. [1]. To understand the dynamics under what circumstances the cancer cells can be eliminated, we implement the theory of optimal control. We design two types of external treatment strategies, one is Adoptive Cellular Immunotherapy and another is interleukin-2. Our aim is to establish the treatment regimens that maximize the effector cell count and minimize the tumor cell burden and the deleterious effects of the total amount of drugs. We derive the existence of an optimal control by using the boundedness of solutions. We characterize the optimality system, in which the state system is coupled with co-states. The uniqueness of an optimal control of our problem is also analyzed. Finally, we demonstrate the numerical illustrations that the optimal regimens reduce the tumor burden under different scenarios.

2020-01-03 | BIOMD0000000897 | BioModels

Optimal Hormone Replacement Therapy in Hypothyroidism - A Model Predictive Control Approach.

Project description: Not available

| S-EPMC9263720 | biostudies-literature

Conventionally Fractionated Adaptive Radiation Therapy of Bladder Cancer an Individualized Approach

Project description:This is a single-arm, prospective, Phase II, multi-center clinical trial designed to demonstrate that adaptive radiotherapy for muscle invasive bladder cancer will translate into a decreased rate of acute gastrointestinal toxicity compared with the historically reported rate for non-adaptive intensity modulated radiation therapy (IMRT).

| 2710638 | ecrin-mdr-crc

A control theory approach to optimal pandemic mitigation.

Project description: Not available

| S-EPMC7894916 | biostudies-literature

Optimal approach in early breast cancer: Radiation therapy.

Project description: Not available

| S-EPMC4041558 | biostudies-literature

Interleukin-17 mediated paracrine network promote tumor resistance to anti-angiogenic therapy

Project description:While angiogenesis inhibitors have provided significant clinical benefit as cancer therapeutics, the mechanisms of anti-VEGF resistance remain incompletely understood. We uncovered an interleukin-17 mediated paracrine network of signaling between the adaptive and innate immune system associated with resistance to anti-VEGF treatment in multiple tumor models. The expression of tumor-associated fibroblasts and tumor-associated granulocytes (defined as CD11b+Gr1+) and tumor-associated monocytic cells (defined as CD11b+Gr1-) were compared between wildtype and IL-17RC knockout tumor bearing mice.

2013-06-27 | E-GEOD-48329 | biostudies-arrayexpress

Interleukin-17 mediated paracrine network promote tumor resistance to anti-angiogenic therapy

2013-06-27 | GSE48329 | GEO

Characterization of resistance to tumor-localized interleukin-2 and interleukin-12 therapy in pet dogs with advanced malignant melanoma

Project description:Pet dogs with oral melanoma were treated in a dose-escalation trial with collagen-anchored interleukin-2 and interleukin-12 following a single 9Gy dose of radiation therapy. Dogs that progressed during, or after, treatment and were ultimately euthanized had tissue collected from primary and metastatic tumors to analyze gene expression and assess mechanisms of resistance to this therapy.

2024-01-29 | GSE253243 | GEO

Effects of tocilizumab versus methotrexate therapy on gene expression profiles in the early rheumatoid arthrtis synovium

Project description:Rheumatoid arthritis (RA) is a chronic, systemic autoimmune inflammatory disease that is characterized by the presence of inflammatory cytokines, including interleukin-6 (IL-6). Here, we investigated the global molecular effects of Tocilizumab, an approved humanized anti-IL6 Receptor antibody, versus Methotrexate therapy, in synovial biopsy samples collected prospectively in early RA before and 12 weeks after administration of the drug. The results were compared with our previous data, generated in prospective cohorts of Adalimumab- and Rituximab-treated (Methotrexate- and anti-TNF-resistant, respectively) RA patients. We found that Tocilizumab induces a significant down-regulation of genes included in specific pathways: cytokines & chemokines (e.g. IL-6, IL-7, IL-22, CCL8, CCL11, CCL13, CCL19, CCL20), and T cell activation. By contrast, Tocilizumab induces a significant up-regulation of genes associated with healing processes. These effects are significantly more pronounced as compared to Methotrexate, Rituximab, or Adalimumab therapies. By opposition to the effects of Adalimumab, Tocilizumab therapy does not induce a decreased expression of genes involved in cell proliferation. Paired synovial biopsy samples were obtained from the affected knee of early RA patients before and 12 weeks after initiation of Tocilizumab (n=12) or Methotrexate (n=8) therapy. SDAI remission criteria were computed prospectively before, 3 months and 6 months after administration of the drugs and patientsM-bM-^@M-^Y responses were defined according to their SDAI remission status at 6 months. Gene expression studies were performed using GeneChip Human Genome U133 Plus 2.0 arrays.

2013-12-30 | E-GEOD-45867 | biostudies-arrayexpress

Uniform optimal framework for integrative next-gen sequence analysis

Project description:Here, we have collapsed multiple analysis problems into two coherent categories, signal detection and signal estimation and adapted linear-optimal solutions from signal processing theory. Our algorithms for detection (DFilter) and estimation (EFilter) extend naturally to integration of multiple datasets. In benchmarking tests, DFilter outperformed assay-specific algorithms at identifying promoters from histone ChIP-seq, binding sites from transcription factor (TF) ChIP-seq and open chromatin regions from DNase- and FAIRE-seq data. EFilter similarly outperformed an existing method for predicting mRNA levels from histone ChIP-seq data (Spearman correlation: 0.81 - 0.89). We performed H3K4me3 and H3K36me3 ChIP-seq on e11.5 mouse forebrain and used DFilter and EFilter to predict promoters and developmental gene expression, uncovering plausible gene targets for SNPs associated with neurodevelopmental disorders. Generated two histone modifiction ChiP-seq in developing embryo mouse forebrain and using them for making bioligical inferences

2013-06-10 | E-GEOD-34073 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data